Study Design. A prospective cohort. Objective. The aim of this study was to prospectively observe donor site pain, health-related quality-of-life outcomes, and complications following harvest of tricortical anterior iliac crest bone graft (AICBG) for anterior cervical discectomy and fusion (ACDF). Summary of Background Data. Persistent donor site pain from the anterior iliac crest has been reported to range between 2% and 40%. This morbidity has led surgeons to consider interbody alternatives for ACDF, which carry additional costs. Methods. We prospectively enrolled 50 patients from 2 tertiary care centers over the course of 1 year observing complications and patient-reported outcomes. Patients filled out SF-12 and numeric rating scale (NRS) for pain in the arm, neck, and donor site pre-operatively and at 1 week, 2 weeks, 6 weeks, 3 to 6 months, and 1 year postoperatively. Outcomes were compared with a control group undergoing ACDF with allograft or Polyether ether ketone cages at 1 year. Results. The mean AE SD donor site pain at 1 week was 5.6 AE 2.8 but decreased to 2.2 AE 2.4 at 6 weeks and 1.1 AE 1.8 at 1 year (P < 0.001). Including the 3 patients who were lost to follow-up, 10% of patients may have experienced persistent moderate or worse pain at 1 year. Linear regression analysis demonstrated that preoperative opioid use was an independent risk factor for increased donor site pain at 1 and 2 weeks (P < 0.05). There were no differences in outcomes at 1 year compared with the nonautograft group. There were 2 (4%) minor wound complications, both treated successfully with oral antibiotics. Conclusion. Tricortical AICBG for ACDF is not associated with major complications and only 4% of patients (potentially, maximum of 10%) experienced moderate, persistent donor site pain at 1 year. There is no difference in health-related outcomes between patients who have autograft with those who did not at 1 year. Preoperative opioid use is associated with increased donor site pain within the first 2 weeks postoperatively but not in the long term. At 6 weeks postoperatively, patients can expect the majority of their donor site pain to be resolved.
A utologous iliac crest bone graft has long been considered the gold standard in many surgical procedures across various specialties. [1] [2] [3] [4] [5] This is due in part to its biological and nonimmunogenic properties, as well as ability to induce fusion. 1, [5] [6] [7] However, various donor site complications have led surgeons to question whether the morbidity is worth the benefit of the high fusion rates. The most common complication following harvest from the anterior iliac crest is persistent donor site pain that has ranged from 2% to upwards of 40%. 1, [4] [5] [6] [7] [8] [9] Other complications that have been described include fracture, 10 hematoma/seroma, sensory abnormalities, 11 poor cosmetic appearance, 12, 13 and visceral complications. 6, 14, 15 The morbidity that patients reportedly face has led many surgeons to consider other alternatives such as allograft or synthetic substitutes for spinal fusion. Although alternative interbody grafts lack donor site morbidity, it does cost significantly more.
This prospective study was conducted to evaluate donor site pain after anterior iliac crest bone graft (AICBG) harvest for anterior cervical discectomy and fusion (ACDF) using a consistent procedure. The primary aim of this study is to assess donor site pain after AICBG harvest by using outcome measures evaluating pain and health-related quality of life (HRQoL) at set intervals postoperatively. Our secondary aim is to assess other complications from bone graft harvest. We also aim to assess HRQoL outcomes in patients undergoing ACDF with autograft compared with a control group of patients undergoing ACDF without autograft. We hypothesize that patients do not experience significant, persistent donor site pain after AICBG harvest, they have similar HRQoL outcomes compared with those who did not have AICBG harvest, and complications from AICBG are rare.
MATERIALS AND METHODS
A prospective study was designed with institutional review board approval from two tertiary care centers between December 2011 and December 2012. Inclusion criteria consisted of English-speaking patients over the age of 18 who were undergoing primary ACDF with tricortical AICBG and willingness to participate in the study. Patients chose whether or not to undergo ACDF with autograft after a discussion with the authors and weighing the benefits and risks in a shared decision-making model. If patients decided to receive autograft, they were offered inclusion in our study. Exclusion criteria consisted of individuals who underwent previous iliac crest bone harvesting and history of severe pelvic and hip conditions that can interfere with the outcome assessment of the study.
A control group of consecutive patients during the same time period with 1-year follow-up undergoing ACDF with allograft or Polyether ether ketone (PEEK) cages was obtained through our institution's prospective spine registry to compare HRQoL over time. Those who were included underwent ACDF with either allograft or PEEK cages on the basis of surgeon preference. This group of patients was included in our study with institutional review board exempt status, as all patients undergoing elective spine surgery at our institution are enrolled into a prospective Web-based registry. Enrollment into this prospective registry has become standard of care at our institution.
Surgical Technique
The senior authors (JDK and CJD) oversaw anterior iliac crest harvest in the same manner for each patient. The anterior superior iliac spine (ASIS) was identified and a curvilinear incision was made approximately 2 cm posterior from the ASIS. Dissection with electrocautery was continued down through the fascial plane wherein the tensor fascia lata and abdominal oblique muscles join exposing the iliac crest. An approximately 1 cm long by 1.5 cm deep tricortical piece of the iliac crest was obtained using a microsagittal saw. In those patients who required 2 or 3-level fusions, grafts were extended to be 2 and 3 cm long, respectively. The edges were smoothed by application of bone wax. After hemostasis was achieved, the cavity was packed with gel foam that had been soaked in 10 mL of 0.25% bupivacaine (Hospira Inc., Lake Forest, IL). The fascia of the oblique muscles and tensor fascia lata was reattached and a layered closure was performed. The skin was closed with a running subcuticular stitch and no drain was used for the iliac crest bone graft harvest site.
Data Collection
Demographic information was collected following consent that included age, gender, body mass index (BMI), smoking history, and the amount of opioids utilized before surgery by patient self-report averaged over the course of 1 month converted to morphine equivalents (MEA). 17 Increased preoperative opioid use has been associated with worse outcomes following spine surgery 18 and we sought to account for this in our study. Similar demographic information was obtained for the control group when possible.
Once patients were enrolled, a questionnaire was administered that consisted of a numeric rating pain scale (NRS) for the neck as well as the arm on a 0 to 10 range, with the arbitrary categories of 0 being no pain, 1 to 3, mild pain, 4 to 7, moderate pain, 8 to 9, severe pain, and 10 being the worst pain imaginable. In addition, patients completed the Short Form-12 (SF-12) preoperatively to assess HRQoL. Following surgery, data were collected from the operative reports that included number of levels fused, operative time, and any immediate complications related to the donor site.
The SF-12 and NRS for neck, arm, and donor site were then administered by telephone postoperatively at 1 week, 2 weeks, 6 weeks, 3 to 6 months, and 1 year. The patients were asked specifically to assess pain from the site of iliac crest bone harvest. Postoperative opioid use was recorded at each interval and complications relating to surgery were obtained. Patients who were unable to be contacted by telephone at a specific interval were asked retrospectively to back fill missing follow-ups if they were eventually reached. We accounted for these delays by documenting the postoperative days passed until the patient was reached for that particular missing follow-up. Once patients endorsed no pain from the donor site, data were only collected at scheduled clinic visits if attended. Minor complications were defined as those that resulted in no longterm disability, while major complications represented those that required repeat surgery, readmission, prolonged hospital stay, or long-term disability. 7 Statistical analysis was completed using SPSS v.22 (IBM Corp, Armonk, NY). To assess for the effect of time within subjects, a repeated-measures analysis of variance (ANOVA) was performed for the NRS for the arm, neck, donor site, and the SF-12 mental component score (MCS) and physical component score (PCS) across our follow-up periods. Multiple linear regression analysis was performed at each follow-up interval evaluating our dependent variable, donor site pain, while controlling for independent variables: age, gender, BMI, preoperative MEAs, and number of levels fused. These covariates were identified preoperatively as possible causes for increased donor site pain postsurgically. Time to donor site pain of mild or less ( 3 on NRS) and Kaplan-Meier curves were also calculated.
Differences between the nonautograft control group and the study group were analyzed by independent t tests for continuous variables and Chi-square tests for categorical data. Multiple linear regression analysis was also performed to evaluate our dependent variables, 1-year SF-12 PCS and MCS, while controlling for our relevant covariates as well as whether autograft was utilized.
RESULTS
Fifty consecutive patients undergoing ACDF at 2 tertiary care centers were prospectively enrolled over a 1-year period. The mean (SD) follow-up for our cohort was 296 days (125). At 1 year, 31 patients who attended their final clinic visit or had persistent pain were evaluated. Sixteen additional patients did not attend their final clinic visit, but all 16 did not endorse donor site pain at the prior clinic visit. Three patients (6%) were considered lost to follow-up, as they had donor site pain at the time of their last questionnaire. Two of the patients had NRS donor site pain of 5 at the 2-week questionnaire and the other patient had a score of 4 at 6 weeks. These patients were included in our statistical analysis. Demographic and clinical characteristics are given in Table 1 .
The mean NRS pain score at the neck and arm decreased significantly over the follow-up period from 5.6 AE 2.6 and 5.4 AE 2.8, to 1.9 AE 2.4 and 2.02 AE 3.0, respectively, after 1 year (P < 0.001). The SF-12 PCS increased significantly (P < 0.001) over the study time period, but the SF-12 MCS did not increase (P ¼ 0.208). A repeated-measures ANOVA with a Greenhouse-Geisser correction determined that the mean NRS for the donor site pain decreased significantly over the course of our study (P < 0.001). Posthoc testing using the Bonferroni correction demonstrated a small and nonsignificant decrease between the first and second postoperative weeks (5.6 AE 2.8 to 4.2 AE 2.8, P ¼ 0.180). At 6 weeks, there was a significant decrease in donor site related pain compared with the first week (P < 0.001), second week (P < 0.001), and 1 year (P ¼ 0.05). There was not a significant difference between pain at 6 weeks and 3 to 6 months (P ¼ 1.00) or between pain at 3 to 6 months and 1 year (P ¼ 0.237). This suggests that patients experience their first significant decrease in donor site pain 6 weeks postoperatively and do not experience additional significant decreases in pain until 1 year after surgery. Repeated-measures ANOVA results are given in Table 2 . The percentage of patients experiencing moderate or worse pain (>3) decreased at each interval from 72% at 1 week to 48% at 2 weeks, 24% at 6 weeks, and 12% at 3 to 6 months. Only 2 patients (4%) experienced persistent donor site pain of at least moderate intensity (>3) at 1 year. Including the 3 patients who were lost to follow-up, 10% of patients may have experienced persistent moderate or worse pain at 1 year. The median time following surgery for resolution of pain to a level of mild or better ( 3 on NRS) was 49 days [95% confidence interval (95% CI) 35.9-62.1] (Figure 1 ). The only independent risk factor of donor site related pain in multivariable linear regression analysis (Table 3) was preoperative MEAs utilized during the first and second postoperative week (P ¼ 0.014 and 0.017, respectively).
We observed 2 (4%) minor complications at the donor site in our cohort over the course of 1 year all occurring within the first 2 weeks. We had 1 superficial wound infection and a postoperative hematoma, both of which were treated successfully with close observation and oral antibiotics. We did not observe any deep wound infections that required a reoperation or readmission to the hospital.
The control group of patients obtained from our prospective spine registry undergoing ACDF without autograft consisted of 135 patients with at least 1-year follow-up. Demographic and comparative analysis between the nonautograft control group and the study group who underwent AICBG harvest is given in Table 1 . There were no differences in SF-12 between those in the registry who underwent autograft and our cohort. Although there was not a difference between the 1-year SF-12 PCS and MCS between the groups (P ¼ 0.743 and 0.740, respectively), the groups were not completely matched with regard to BMI and preoperative SF-12 MCS. After controlling for both clinically and statistically significant covariates, obtaining autograft was not a negative independent predictor of 1-year SF-12 PCS or MCS scores (P ¼ 0.574 and 0.102) in multivariable linear regression analysis (Tables 4  and 5 , respectively).
DISCUSSION
In this prospective study evaluating donor site related pain following harvest of AICBG for ACDF, we found at worst 10% of patients endorsed donor site pain described as at least moderate after 1 year and there was no difference in outcomes at 1 year compared with a control group who did not receive tricortical autograft. There was an association between increased donor site pain within the first 2 weeks and preoperative opioid use. We observed only 2 (4%) minor complications that resolved without any additional surgical intervention, which is consistent with prior studies that describe a range of 1% to 15%. 1, 5, 9, 11, [19] [20] [21] [22] The literature specifically evaluating donor site related pain following tricortical AICBG harvest for spine is limited both in size and quality. Skeppholm et al 22 demonstrated that at 4 weeks, patients reported an average VAS score at the donor site of 2.7 and 1.1 at 1 year. Our study helps fill in the time before the first follow-up as we evaluated patients at both 1 and 2 weeks postoperatively. The data from our study support the downward trend in donor site pain, as we found pain scores to be 4.2 AE 2.8 at 2 weeks and 2.2 AE 2.4 at 6 weeks.
We found that increased preoperative opioid use was significantly associated with donor site pain within the first 2 weeks of surgery. This is likely due to opioid hyperalgesia, as patients who use opioids chronically can develop excitatory changes in the central nervous system that both increase pain transmission and sensitivity to new pain. 23, 24 This association did not continue later on suggesting that increased preoperative opioid use is not an independent risk factor for chronic donor site pain following AICBG harvest. An increase of 20 MEAs is expected to be associated with an increase of around 1 on the NRS following AICBG during the first 2 weeks equating to an approximately 17% to 24% increase in early donor site pain.
When comparing our cohort of patients who underwent AICBG harvest for ACDF with a time-matched cohort of patients who did not, obtaining autograft was not an independent risk factor for decreased 1-year SF-12 PCS or MCS when controlling for differences between the groups and other clinically significant factors.
This study improves our knowledge of the natural history of donor site related pain following tricortical AICBG harvest for ACDF over time. The strengths of this study are the prospective design from 2 tertiary care centers with the primary outcome evaluating donor site related pain at multiple early intervals using the same standard procedure. Prior studies were retrospective, 5 did not design the study to evaluate donor site pain, 22 or evaluated pain after the acute pain had resolved. 9, 25 We utilized a time-matched consecutive cohort of patients who did not undergo AICBG harvest to compare global outcomes at 1 year and did not find a difference when controlling for significant covariates. The weaknesses of the paper are with the relatively low number of patients enrolled in our cohort; however, it is the largest prospective cohort evaluating donor site related pain in spine patients that we know of. Our primary endpoint of donor site pain of zero is a potential limitation, as there may be patients who develop pain later on. At the 1-year mark, 34 of 50 patients previously reported no donor site pain at prior visits but may have developed pain later on. The statistically significant decrease in donor site pain from 6 weeks to 1 year (2.2 to 1.1 on NRS) is of questionable clinical significance. Prior evaluations have placed the minimal important change for the NRS at 2. 26 Although we demonstrated a 4% (possibly maximum 10%) rate of moderate, persistent donor site pain at 1 year, these patients could be experiencing an unacceptable amount of pain and may not have chosen autograft in retrospect. The 3 patients who were lost to follow-up given our small patient cohort could have introduced a major bias. These patients contributed to our worstcase scenario of 10% of patients with moderate pain or worse after 1 year and may have benefitted more following surgery without autograft. Lastly, contacting patients by telephone to retrospectively back fill missing follow-ups could have introduced both interviewer and recall bias.
CONCLUSION
The harvest of tricortical anterior iliac crest bone graft for ACDF is well tolerated without significant complications and at 1-year outcomes are no different than ACDF without AICBG harvest. Only 4% of patients (maximum 10%) at 1 year experienced persistent, moderate pain. Preoperative opioid use was associated with increased donor site pain within the first 2 weeks postoperatively but not in long term. We advocate educating patients on minimizing opioid use preoperatively to improve early postoperative pain. Providers may counsel patients to expect the majority of their donor site pain to be resolved by 6 weeks postoperatively, but improvements may continue until 1 year. As the cost of allografts, cages, and growth factors continue to add to the overall cost of spine surgery, consideration should continue to be given to local tricortical autograft as a viable and potentially cost-saving option in ACDF.
